Belgian neurotechnology startup ReVision Implant has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its visual cortical prosthesis, Occular, clearing the way toward first-in-human clinical trials.
The Occular system is designed to restore functional vision in people with severe blindness, including patients whose condition cannot be treated with retinal implants or optic nerve therapies.
Unlike most experimental vision-restoration technologies, which rely on stimulating the retina, the Occular system interfaces directly with the brain’s visual cortex, enabling it to bypass damage to the eye or optic nerve.
The system applys a miniature camera mounted on a wireless headset to capture visual information. This data is transmitted to a brain implant that stimulates neurons in patterns interpreted by the brain as points of light. These signals combine to form simple visual representations that may support applyrs identify objects and navigate their surroundings.
Development of the technology launched in 2020. ReVision Implant declares the system has undergone extensive preclinical testing, including long-term animal studies lasting more than two years. In contrast to other neurotech companies, ReVision has focapplyd on long-term performance from the start.
The Breakthrough Device designation will allow ReVision Implant to obtain early feedback on their regulatory roadmaps, data, and clinical trial protocols, and also grants them access to the FDA’s Total Product Life-Cycle Advisory Program (TAP) Pilot.
The award is also testament to the high quality of the firm’s medical research, with only 160 medical devices receiving Breakthrough status throughout 2025.
A first short-term clinical trial during a scheduled brain surgery is foreseen for October 2026. The company expects to launch early-stage human clinical trials in blind volunteers as soon as summer 2027, subject to regulatory approvals.
Frederik Ceyssens, CEO of ReVision Implant declared: “While cochlear implants have transformed treatment for hearing loss, there is still no widely available neuroprosthetic solution for restoring vision.
“Our aim is to provide people living with severe blindness with functional vision that improves indepconcludeence and quality of life.”
Globally, an estimated tens of millions of people live with severe vision loss, with many having conditions that cannot be treated utilizing current surgical or pharmaceutical approaches.
Becaapply the Occular implant stimulates the visual cortex directly, the technology may be suitable for patients with a wide range of blindness caapplys, including retinal degeneration and optic nerve damage.
If clinical trials are successful, ReVision Implant declares it believes the system could benefit a large proportion of patients with untreatable blindness, about 650,000 in the US and the EU combined according to the company.
Leave a Reply